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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effectiveness and safety of exercise or physical activity interventions, or both, on the disease-related physical and mental
health of individuals diagnosed with non-advanced colorectal cancer, staged as T1-4 N0-2 M0, treated surgically with or without
neoadjuvant or adjuvant therapy (i.e. chemotherapy, radiotherapy or chemoradiotherapy).
B A C K G R O U N D
Description of the condition
Colorectal cancer is the third most commonly diagnosed cancer
and the fourth leading cause of cancer death worldwide, account-
ing for an estimated 694,000 deaths in 2012 (Ferlay 2013). Inci-
dence and mortality rates vary globally, with higher incidence and
lower mortality rates in higher-income countries (Arnold 2015;
Ferlay 2013; Stewart 2014). In general, incidence is higher in men
than women and is strongly linked with age, with highest inci-
dence among people aged 65 to 74 years (Howlader 2016). Inci-
dence is currently stabilising in high-income countries, however
a two-fold cumulative increase in incidence is expected by 2025,
due to increasing incidence in low- to middle-income countries.
With development, comes the adoption of more inactive lifestyles
and unhealthy dietary habits; established risk factors for colorec-
tal cancer (Stewart 2014). This is expected to increase the global
burden of colorectal cancer, which may be compounded by a lack
of health service resources in low- and middle-income countries
to deal with the escalation in incidence (Stewart 2014).
Five-year survival from colon and rectal cancer has reached 60% or
more in 22 countries worldwide (Allemani 2015). Between 1989
and 2011, colorectal cancermortality rates decreased bymore than
25% and 30% in men and women respectively in high-income
countries in Northern and Western Europe but increased in most
Eastern European countries (Ouakrim 2015). Similar trends are
evident globally, with decreasing mortality rates in high-income
countries, including Australia, Canada (Coleman 2011), the USA
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(Ryerson 2016) and Japan (Arnold 2015), and contrasting increas-
ing mortality rates in low- and middle-income regions, such as
Latin America and the Phillipines (Arnold 2015). These dispar-
ities are not easily explained and are likely due to differences in
access to diagnostic and treatment services (Haggar 2009), with
advancements in treatment and early detection contributing to
decreasing mortality in high-income countries (Coleman 2011;
Stewart 2014).
Although treatments are advancing, anti-cancer therapies are as-
sociated with a range of adverse physiological and psychological
side effects, which affect morbidity and mortality (Devin 2016).
Surgical resection is the primary treatment modality for stage I-III
(T1-4 N0-2 M0) colorectal cancer, with systemic chemotherapy
or radiotherapy (more often in rectal cancer), or both, given either
in the adjuvant or neoadjuvant setting in stage III and high-risk
stage II patients (El-Shami 2015; Labianca 2010). Major abdom-
inal surgery alone has been associated with declines in physical
function (Schroeder 1991) and fatigue (Christensen 1982). Can-
cer-related fatigue affects between 60% to 96%of people with can-
cer during and following chemotherapy, radiotherapy or surgery
(Cramp 2012; Thomas 2014; Wagner 2004). It is a distressing
symptom defined as a sense of “physical tiredness or exhaustion
related to cancer or cancer treatment” (NCCN 2016), which can
interfere with one’s ability to carry out daily activities (Curt 2000)
and negatively affect mood and quality of life (Stone 2008). Can-
cer-related fatigue is present in some colorectal cancer survivors at
four years following diagnosis (Schneider 2007). Physical inactiv-
ity has been identified as both a risk factor for (Bower 2014), and
a consequence of (Lynch 2010) cancer-related fatigue.
Declines in cardiorespiratory fitness can occur following treatment
for colorectal cancer (Devin 2016; West 2014a). Lower levels of
cardiorespiratory fitness are linked with higher rates of cancer-
specific morbidity and mortality (Peel 2009; Schmid 2015), and
can predict morbidity after colonic (West 2014b) and rectal (
West 2014c) surgery. Furthermore, people with colorectal cancer
may be susceptible to sarcopenic obesity (obesity with depleted
muscle mass), which is associated with poorer functional status
and poorer survival rates (Prado 2008;Wang 2017). These adverse
effects, alone or in combination can impact adversely on a patient’s
quality of life and subsequent physical activity levels (Cramer
2014a). Colorectal cancer survivors are also at an increased risk of
developing second colorectal cancers (Green 2002; Markle 2010),
non-colorectal cancers (Birgisson 2005) and other co-morbidities
(Denlinger 2011).
Concerns surrounding recurrence are common, affecting over half
of cancer patients at one year following diagnosis (Baker 2005).
Even at five years following surgery for colorectal cancer, survivors
have concerns surrounding recurrence (Custers 2016). A signifi-
cant minority of colorectal cancer patients and longer-term sur-
vivors of colorectal cancer (two or more years post diagnosis) ex-
perience clinically meaningful levels of psychological distress, in-
cluding symptoms of anxiety and depression or reduced mental
well-being (Mosher 2016). Colorectal cancer survivors report high
quality of life at five years or longer post diagnosis but have higher
rates of depression than age-matched populations (Ramsey 2002).
Psychological outcomes vary greatly in this population, poorer psy-
chological outcomes have been linkedwith the presence of existing
co-morbidities (Lynch 2008; Ramsey 2002), worse general health
(Yost 2008) and lower socioeconomic status (Ramsey 2002). Lev-
els of anxiety and depression are reported to be higher in people
who undergo surgery with adjuvant chemotherapy or radiother-
apy compared with surgery alone (Pereira 2012).
Description of the intervention
Exercise and physical activity interventions will be the focus of
this review. Physical activity is defined as any bodily movement
produced by contraction of skeletal muscle that results in en-
ergy expenditure above resting energy expenditure (ACSM 2009;
Caspersen 1985). Exercise is a subset of physical activity that is
planned, structured and repetitive, done to improve or maintain
one, or more of the components of physical fitness (ACSM 2009;
Caspersen 1985). Physical activity interventions may be less struc-
tured than exercise interventions and often focus on promoting
the integration of activities into daily life (e.g. gardening, walking
or active travel). Exercise and physical activity interventions may
be self-directed or supervised by a healthcare professional. They
can involve aerobic or resistance training, flexibility or balance
training, or a combination of these, can take place in any setting
and can be individual or group based, or both. No restrictions will
be made regarding frequency, intensity, time or type of exercise
or physical activity intervention included. Interventions will last
a minimum of four weeks, to exclude studies on the acute effects
of exercise or physical activity.
Exercise and physical activity interventions are not currently de-
livered as part of standard practice during or following treatment
for colorectal cancer. Early postoperative mobilisation is, how-
ever, strongly recommended, as part of the Enhanced Recovery
After Surgery (ERAS) guidelines following colorectal surgery, en-
couraging patients to be out of bed for two hours on the day of
surgery and six hours per day, thereafter until discharge (Lassen
2009). The AmericanCollege of SportsMedicine (Schmitz 2010),
the American Cancer Society (Rock 2012) and the British Asso-
ciation of Sport and Exercise Science (BASES 2011) guidelines
confirm that exercise can be safely performed during and follow-
ing cancer treatment in the general cancer population. Specific
guidance statements on exercise and physical activity interven-
tions during and following treatment for colorectal cancer have
not yet been published, due to lack of evidence on adverse effects
and lack of safety data (Schmitz 2010). Side effects of treatments
(cancer-related fatigue, peripheral neuropathy, immune suppres-
sion, digestion issues, bowel dysfunction (including faecal inconti-
nence) and urinary incontinence) may increase the risk of adverse
events during exercise and physical activity. These side effects may
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represent barriers to exercise and physical activity participation
(Denlinger 2009; Denlinger 2011; Rock 2012; Schmitz 2010).
Indeed, chronic diarrhoea is a side effect that has been associated
with limitations in activity and negative body image (Schneider
2007). The presence of a stoma is also associated with diminished
body image (Hong 2014). These side effects have been highlighted
as factors to consider when prescribing exercise or physical activity.
Existing co-morbidities (most commonly cardiovascular disease,
musculoskeletal problems and lung or breathing problems), par-
ticularly in older people with colorectal cancer have been high-
lighted as other factors requiring consideration, to reduce the risk
of injury and adverse events (Denlinger 2009; Rock 2012; Schmitz
2010).
How the intervention might work
Physical activity and exercise have been proposed as non-phar-
macologic interventions to attenuate the negative physiologic and
psychologic effects of treatment in people with cancer (Courneya
2007; Schmitz 2005). There is a growing body of evidence from
Cochrane and non-Cochrane systematic reviews demonstrating
the positive impact of physical activity and exercise both dur-
ing and following cancer treatment (Galvao 2005; Knols 2005;
Schmitz 2005; Speck 2010). Exercise training improves car-
diorespiratory fitness and muscle strength (Schmitz 2005; Speck
2010), overall health-related quality of life (HRQoL) (Knols 2005;
Mishra 2012a; Mishra 2012b), and cancer-related fatigue (Cramp
2012; Furmaniak 2016; Speck 2010) in the general cancer popu-
lation during and following cancer treatment, and physical func-
tioning during treatment (Mishra 2012a). Through improved car-
diorespiratory fitness and muscle strength, physical activity and
exercise may help address the physical deconditioning associated
with cancer treatments (Speck 2010; Schmitz 2005) and help
manage cancer-related fatigue (Al-Majid 2009; Cramp 2012).
Physical activity and exercise may also help the emotional and
mental aspects of cancer-related fatigue (Al-Majid 2009; Cramp
2012). Benefits of exercise interventions on psychological well-
being (Knols 2005), anxiety and depression show positive trends
but the evidence is not consistent (Cramp 2012; Furmaniak 2016;
Mishra 2012a).
Cardiorespiratory fitness has been highlighted as an independent
predictor of cancer mortality risk. Higher cardiorespiratory fitness
is associated with a significant reduction in total cancer mortality
(Schmid 2015) and colorectal cancer mortality (Peel 2009). Peel
and colleagues report that men with at least a moderate fitness
level had a 42% lower risk of colorectal mortality compared with
men with a low cardiorespiratory fitness level. Evidence from ob-
servational studies suggest that physical activity is associated with
overall and disease-free survival (Haydon 2006;Meyerhardt 2006;
Meyerhardt 2009) in both colon and rectal cancer patients.
There is consistent evidence linking physical activity to reduced
colon cancer risk (Leitzmann 2015;Wolin 2009). A meta-analysis
of 52 studies found an inverse association between physical activity
and colon cancer, with an overall relative risk reduction (RR) of
24% (Wolin 2009). This is consistent with findings of an earlier
meta-analysis of 19 cohort studies, which demonstrated a lower
risk of colon cancer of 22% and 29% in physically active men and
women respectively (Samad 2005). Conversely, there appears to
be no consistent association between physical activity and rectal
cancer risk (Robsahm 2013).
The exact biological mechanisms for the observed benefit of phys-
ical activity and exercise for the prevention and secondary preven-
tion of colorectal cancer are not fully understood. Various mech-
anisms have been proposed. Physical activity and exercise may re-
duce carcinogen exposure in the mucosa through decreased gas-
trointestinal transit time (Quadrilatero 2003; Slattery 2003), may
alter prostaglandin levels (prostaglandins are unsaturated, free fatty
acids that affect colonic function) (Quadrilatero 2003) andmay al-
ter the insulin-like growth factor (IGF) pathway (Denlinger 2011;
Fairey 2003). In people with colorectal cancer, moderate-intensity
exercise has resulted in reduced levels of urinary markers of oxida-
tive damage (Allgayer 2008) and decreased interleukin-1 receptor
agonist (Allgayer 2004), which may enhance immune function.
Oxidative DNA damage is thought to be involved in tumour for-
mation and may be associated with malignant transition and re-
currence (Allgayer 2008). IGF-1 is important for cellular prolifer-
ation and survival (Hursting 2010), higher levels of which may be
associated with increased risk of colorectal cancer (Giovannucci
2000), but this association remains elusive. Decreases in IGF and
increases in IGF-binding proteins have been observed following
exercise training in breast cancer survivors, whichmay be clinically
relevant for the colorectal cancer population (Fairey 2003)
Physical activity and exercise may therefore be potentially effective
in improving overall and disease-free survival. Indeed, given that
regular physical activity can decrease the risk of colon cancer and
has improved cardiorespiratory fitness, muscle strength, HRQoL
and cancer-related fatigue in other cancer populations, it may be
of clinical relevance for the colorectal cancer control continuum.
Why it is important to do this review
Colorectal cancer is a major public health problem.With the pro-
jected increasing incidence of colorectal cancer in developing re-
gions, the increasing mortality rates in low- and middle-income
countries and 3.5 million colorectal cancer survivors worldwide
(Stewart 2014), there is a requirement to develop effective inter-
ventions that aid physical and psychological recovery, help alle-
viate treatment side effects and increase overall and recurrence-
free survival. The Lancet Oncology commission have prioritised
the reduction in morbidity and mortality associated with cancer,
with a focus on “less toxic”, “cost effective” interventions (Sullivan
2011). There is therefore a need for a greater understanding of
the effects of exercise and physical activity interventions on the
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disease-related physical and mental health of individuals with col-
orectal cancer, for policy, practice and for consumers.
To date, there is one published non-Cochrane systematic review
on exercise interventions for people with colorectal cancer that
complements this review (Cramer 2014b). No recommendations
regarding exercise as a routine intervention for people with col-
orectal cancer were made following this review due to insufficient
evidence and lack of safety data. The reviewundertaken byCramer
and colleagueswas limited to individualswho had completed treat-
ment. This review will be broader, and will include those who are
receiving adjuvant therapy in addition to those who have finished
treatment, in which there has been no previous review undertaken.
This review is important in order to update current evidence and
include emerging evidence in relation to exercise and physical ac-
tivity interventions for individuals with colorectal cancer and to
identify current evidence gaps.
O B J E C T I V E S
To assess the effectiveness and safety of exercise or physical activity
interventions, or both, on the disease-related physical and mental
health of individuals diagnosed with non-advanced colorectal can-
cer, staged as T1-4 N0-2 M0, treated surgically with or without
neoadjuvant or adjuvant therapy (i.e. chemotherapy, radiotherapy
or chemoradiotherapy).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will consider all randomised control trials (RCTs) and clus-
ter-RCTs comparing exercise or physical activity interventions, or
both, to usual care or no exercise or physical activity intervention
for inclusion in this review.
Types of participants
Wewill include trials that evaluate the effect of exercise or physical
activity interventions, or both, on adults (aged 18 years or over),
regardless of gender, diagnosed with non-advanced colorectal can-
cer, staged as T1-4,N0-2, M0, treated surgically with or without
neoadjuvant or adjuvant therapy (i.e. chemotherapy, radiotherapy,
chemoradiotherapy). We will include trials that examine exercise
or physical activity interventions, or both, delivered during ad-
juvant therapy, following adjuvant therapy or following surgery
alone. We will exclude studies including participants with other
cancer types, unless outcomes for colorectal cancer are reported
separately and trials including participants who are more than five
years post-diagnosis.
Types of interventions
We will compare exercise and physical activity interventions sep-
arately to either no exercise or physical activity intervention or to
usual care. Participants in both the control and intervention arms
will receive the same usual care. Exercise or physical activity ses-
sions can take place in any setting, be supervised, self-directed or
both, can be individual or group based, or a combination of both.
Exercise or physical activity modalities can include aerobic or re-
sistance training, flexibility and balance training or a combination
of these. No restrictions will be made regarding frequency, inten-
sity, time or type of exercise or physical activity intervention. We
will only include studies with interventions that last a minimum
of four weeks in duration, to exclude studies on the acute effects
of exercise or physical activity. We will record specific details on
the intervention according to the FITT-VP (frequency intensity,
time, type, volume, progression) principle (ACSM 2014). We will
classify exercise or physical activity intensity as mild, moderate or
vigorous based on the rate of perceived exertion (RPE), heart rate
(HR) or metabolic equivalents (METS) (ACSM 2014), and use
the author’s classification of mild, moderate, or vigorous when a
quantitative measure is unavailable.
Types of outcome measures
We will extract information for the primary and secondary out-
comes at all available time points. We will seek to analyse overall
survival and recurrence-free survival at 12 months, 3 years and 5
years. We will seek to analyse the other primary and secondary
outcomes according to the length of follow-up: up to 12 weeks
after baseline (immediate); more than 12 weeks but less than 6
months after baseline (short term); more than 6 months but less
than 12 months after baseline (medium term) and more than 12
months after baseline (long term).
Primary outcomes
1. Physical function (e.g. the Karnofsky Performance Status
Scale; the Eastern Cooperative Oncology Group Scale;
percentage of predicted peak oxygen uptake (V02 peak), timed
chair rise test; timed ’Up & Go’ test) or other valid instruments
2. Disease-related mental health (e.g. the Hospital Anxiety
and Depression Scale; the Beck Depression Index)
3. Adverse events (participants experiencing at least one
adverse event e.g. injury, death, adverse events resulting in
discontinuation of the intervention)
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Secondary outcomes
1. Overall survival (time interval between enrolment in the
study and death of the person from any cause)
2. Recurrence-free survival (time interval between date of
enrolment in the study and the date when colorectal cancer
recurs or another cancer occurs during the follow-up)
3. Physical fitness (e.g. cardiorespiratory endurance (six-
minute walk test; 10-metre shuttle walk test; V02 peak or muscle
strength (dynamometry; one repetition maximum; five
repetition maximum) or another valid instrument
4. Cancer-related fatigue (e.g. the Functional Assessment of
Chronic Illness Therapy-Fatigue (FACIT-F); the Schwartz
Cancer Fatigue Scale (SCFS); the Brief Fatigue Inventory (BFI);
the Piper Fatigue Scale (PFS))
5. Anthropometric measurements (e.g. weight, body mass
index (BMI), body composition, waist measurement, skin-fold
measurement)
6. HRQoL (e.g. the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire Core 30
(EORTC-QLQ-C30); the Medical Outcomes Study Short Form
36 General Health Survey (SF-36); the Functional Assessment of
Cancer Therapy - Colorectal scale (FACT-C))
7. Levels of physical activity (e.g. physical activity
questionnaires (International Physical Activity Questionnaire
(IPAQ), Global Physical Activity Questionnaire (GPAQ)) or
objective measures of physical activity using pedometers or
accelerometers)
Search methods for identification of studies
Electronic searches
We will search the following electronic databases up to the latest
issue with no language or date restrictions to identify relevant
RCTs and cluster-RCT’s or this review:
1. The Cochrane Central Register of Controlled Trials
(CENTRAL, in the Cochrane Library) (Appendix 1) (inception
to present)
2. Ovid MEDLINE(R) Epub Ahead of Print, In-Process &
Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid MEDLINE(R) (1946 to Present) (Appendix 2)
3. Ovid Embase (1974 to present) (Appendix 3)
4. CINAHL (in EBSCOhost 1982 to present)
5. Web of Science (1970 to present)
6. PsycINFO (1806 to present)
7. Open Grey (formerly SIGLE) (1980 to present)
8. PEDro (1999 to present)
Cochrane Colorectal Cancer’s Information Specialist will conduct
and verify the searches.
Searching other resources
We will search clinical trials registries separately for ongoing trials
and trial protocols including:
1. Clinical.trials.gov (www.clinicaltrials.gov)
2. The World Health Organization International Clinical
Trials Registry Platform (WHO ICTRP) (apps.who.int/
trialsearch/)
3. The EU Clinical Trials Register (
www.clinicaltrialsregister.eu/)
4. CenterWatch (www.centerwatch.com)
Wewill screen reference lists of all included studies and any relevant
systematic reviews identified. We will handsearch conference and
meeting abstracts of relevant organisations including:
1. American Society of Clinical Oncology (ASCO)
2. European Society for Medical Oncology (ESMO)
3. American College of Sports Medicine (ACSM)
4. BIT’s Annual World Cancer Congress
5. European Multidisciplinary Colorectal Cancer Congress
(EMCCC)
6. European Federation for Colorectal Cancer (EFR)
We will contact individuals or organisations for information on
unpublished or ongoing studies.
Data collection and analysis
Selection of studies
We will import all records retrieved from the searches into End-
Note (Endnote 2016) and remove duplicated records.
Two review authors (MMG and MAT) will independently ex-
amine the studies identified in the literature search. Two review
authors (MMG and MAT) will independently screen all studies
based on their titles and abstracts and will remove studies that ob-
viously do not meet the eligibility criteria. We will record reasons
for exclusion and will not exclude studies solely on the basis of
reporting of outcome data. We will obtain the full texts of po-
tentially eligible studies and the two review authors (MMG and
MAT) will independently examine the studies. The authors will
code the studies as ’include’, ’exclude’ or ’uncertain’ based on the
outlined criteria. We will resolve any disagreements through dis-
cussion, where necessary involving a third review author (CC or
MMC), and keep a record of decisions made.
Data extraction and management
Two review authors (MMG andMAT) will independently extract
data from the studies that meet the inclusion criteria and will
enter data in the Cochrane software Review Manager 5 (RevMan
5) (RevMan 2014) for analyses. We will record extracted data
on a form pre-developed for this purpose. MMG and MAT will
pilot the data extraction form in a random sample of three studies
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to ensure it captures the required information. They will revise
the form as required. We will resolve any disagreements through
discussion, and where necessary refer to a third review author (CC
or MMC). We will extract the following data.
1. Study details; author and year of publication, country of
origin, aim, design, funding source, method of randomisation,
method of recruitment, trial inclusion and exclusion criteria,
duration of participation, conflicts of interest/ethical concerns,
risk of bias assessment
2. Participant details; total number randomised, age, gender,
cancer stage, type of cancer treatment, ethnicity, time since
diagnosis, time beyond active treatment, baseline imbalances
3. Intervention details; exercise type, intensity, frequency,
volume, setting, duration of intervention, supervised or self-
directed, details of control/comparison intervention, adherence/
contamination and co-interventions (e.g. medication use)
4. Outcomes; primary and secondary relevant to this review,
including adverse events, follow-up time points, measurement
tools used for outcomes, limits and direction of effect
Assessment of risk of bias in included studies
Two review authors (MMG and MAT) will independently assess
each included study for risk of bias using the Cochrane ’Risk of
Bias’ tool (the Cochrane Handbook for Systematic Reviews of Inter-
ventions,Chapter 8.5.d, Higgins 2011a; Higgins 2017) (Appendix
4). We will assess random sequence generation, allocation con-
cealment, blinding of personnel and outcome assessment, com-
pleteness of outcome data, selective outcome reporting as sources
of bias and any other sources of bias and classify as ’high’, ’low’ or
’unclear’. Since it is not possible to blind participants to an exer-
cise or physical activity intervention, we will only assess blinding
in relation to study personnel and outcome assessors. We will re-
solve any disagreements through discussion and where necessary,
through involving a third review author (CC or MMC). For each
study, we will detail the risk of bias in table form along with a
statement of justification for our judgement. We will summarise
results in both a ’Risk of bias’ summary figure and ’Risk of bias’
graph (i.e. bar chart). When interpreting treatment effects, we will
take into account the risk of bias for studies that contribute to that
outcome.
Measures of treatment effect
For continuous outcomes (physical function, mental health, phys-
ical fitness, cancer-related fatigue, anthropometric measurements,
levels of physical activity andHRQoL)wewill determine themean
differences (MD) or standardised mean differences (SMD) (in
cases where different instruments are used to measure the selected
outcome), in the intervention group compared with the control
with 95% confidence intervals (CIs). We will extract data for final
scores and change from baseline scores, if available.
For time-to-event outcomes (overall survival and recurrence-free
survival) we will extract hazard ratios (HRs) with standard errors,
assuming that the HR is constant over time to compare the risk
of death or recurrence of cancer in the treatment group with that
in the control group. Where HRs are not presented, we will esti-
mate them from reported data (e.g. Kaplan-Meier curves, logrank
observed minus expected events and the logrank variance) using
methods described by Tierney and colleagues (Tierney 2007).
For dichotomous outcomes (adverse events) we will calculate the
risk ratio (RR) at individual study level by dividing the risk of
an event in the intervention group by the risk of the event in the
control group. We will define RRs greater than 1.0 as favouring
the control group (i.e. fewer adverse events in the control group)
and RRs less than 1.0 as favouring the intervention group (Deeks
2017).
We will use a fixed-effect or random-effects model to calculate
weighted mean differences (WMD) or weighted SMD, weighted
HRs and weighted RRs with 95% CIs. We will use the random-
effects model with inverse-variance weighting wherever possible
due to the nature of exercise as a highly-varied intervention and use
the fixed-effect model when there are few studies or if the studies
are small with few events. In sensitivity analyses, wewill investigate
the effect of the choice of model (fixed-effect or random-effects)
on the pooled estimate.
Unit of analysis issues
For parallel-group, individually randomised trials, the colorectal
cancer participant will be the unit of analysis in each study. We
will include cluster-RCTs, if identified. We will extract data when
cluster-RCTs report appropriate analyses, adjusting for the sample
size in each cluster. Where control of clustering has not been per-
formed we will attempt to correct for the intervention effects of
cluster-RCTs by reducing the size of each trial to its ’effective sam-
ple size’, which is the number of the original sample size divided
by the ’design effect’.We will calculate the design effect as 1 + (M-
1)* ICC, where M is the average cluster size and ICC is the intra-
cluster correlation coefficient as described in the Cochrane Hand-
book for Systematic reviews of interventions section 16.3.4 (Higgins
2011b). We will use an estimate of the ICC derived from the trial
(if possible), from a similar trial or from a study of a similar popu-
lation. If we use ICCs from other sources, we will report this and
conduct sensitivity analyses to investigate the effect of variation in
the ICC. If we identify both cluster-randomised trials and individ-
ually-randomised trials, we plan to synthesise the relevant infor-
mation. Wewill consider it reasonable to combine the results from
both if there is little heterogeneity between the study designs and
the interaction between the effect of intervention and the choice
of randomisation unit is considered unlikely.
For trials reporting multiple follow-up time points, we will con-
duct separate meta-analyses to reflect immediate (less than 12
weeks), short-, medium- and long-term periods of follow-up, if
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appropriate. For immediate follow-up we will extract data closest
to the 12-week follow-up time point. For short- and medium-
term follow-up, we will extract data closest to the six- and 12-
month follow-up time point, respectively. For long-term follow-
up, we will extract the longest time interval.
For trials with multiple arms, we will include only relevant inter-
vention arms. We will combine all relevant intervention arms into
a single group and combine all relevant control arms into a single
group, creating a single, pair-wise comparison.
Dealing with missing data
We will attempt to contact authors of the included studies to
requestmissing data on outcomes, participants and summary data.
We will document reasons for missing data (missing at random
or missing not at random) and how they were addressed. We will
assess the extent to which studies analysed data according to the
intention-to-treat principle. We will assess the level of missing
data for included studies by comparing the number of participants
included in the final analysis with the proportion of all participants
in each study. For studies at high risk of attrition bias, we will
attempt to perform both the best-case and worst-case sensitivity
analyses to assess the impact of missing data on the estimates of
effect.
Assessment of heterogeneity
We will evaluate clinical heterogeneity by examining diversity
in participant characteristics, physical activity and exercise inter-
vention characteristics, colorectal cancer treatment and outcomes
among trials. We will evaluate methodological heterogeneity by
examining diversity in study designs and risk of bias. We will not
pool clinically or methodologically heterogeneous trials. We will
visually inspect forest plots and use the Chi2 test to assess sta-
tistical heterogeneity (with a P value < 0.1). We will use the I2
statistic to assess the percentage of variation across studies that is
due to heterogeneity and not due to chance (Higgins 2003). We
will tentatively regard heterogeneity as ’low’ if I2 is less than 49%,
’moderate’, if I2 is between 50% and 75% and ’high’ if I2 is more
than 75% (Deeks 2017). We will investigate potential sources of
statistical heterogeneity by reassessing diversity in characteristics
of studies (participant, intervention, treatment and outcomes) and
by means of subgroup and sensitivity analysis.
Assessment of reporting biases
If there are at least 10 studies included in a meta-analysis, we will
visually inspect funnel plots for asymmetry to investigate potential
publication bias or small-study effects. We will follow the recom-
mendations in Chapter 10 of the Cochrane Handbook for System-
atic Reviews of Interventions for any statistical testing of funnel plot
asymmetry (Sterne 2017).
We will attempt to control for time-lag bias, location bias, citation
bias and language bias by using a comprehensive search strategy
without language or date restriction, that includes searching for
unpublished studies and searching trials registers. We will control
for multiple publication bias by identifying duplicate publications
of the same study and grouping these together, listing them as one
study. For studies published after 1 July 2005, we will screen the
Clinical Trials Register at theWHO ICTRP for the trial protocols
(apps.who.int/trialsearch) to evaluate whether selective reporting
of outcomes is present (outcome reporting bias).
Data synthesis
We will pool results from comparable groups of trials using both
fixed-effect and random-effects models, if appropriate. Whenever
possible, we will use a random-effects model with inverse-variance
weighting for meta-analyses (DerSimonian 1986) due to the na-
ture of exercise as a highly-varied intervention. We will use a fixed-
effect model when there are few studies or if the studies are small
with few events. We will conduct a sensitivity analysis to inves-
tigate the effect of the choice of model (fixed-effect or random-
effects) on the pooled estimate. MMG and CC will conduct sta-
tistical analysis using RevMan 5 (RevMan 2014).We will consider
a two-sided P value of less than 0.05 as statistically significant.
Where data aggregation is not possible due to heterogeneity, we
will provide a narrative synthesis of study results. We will sum-
marise the findings of the systematic review alongside an assess-
ment of the quality of evidence for each individual outcome using
the GRADE approach (GRADE Working Group 2004).
Subgroup analysis and investigation of heterogeneity
Where there is sufficient data, We will perform subgroup analysis
of the effect of the intervention according to:
1. Exercise and physical activity intervention characteristics
(using frequency, intensity, time, type, volume progression to
calculate METS/hours per week)
2. Participant characteristics (gender, age (over 65 years or
under 65 years))
3. Cancer stage ((T1-2, N0, M0), (T3-4, N0, M0),(T1-4,
N1-2, M0))
4. Cancer type (colon or rectal)
5. Treatment stage (during or post treatment)
6. Treatment type (laparoscopic or open surgery, neoadjuvant
therapy or no neoadjuvant therapy)
7. Time since diagnosis ( zero to one year, two to three years,
four to five years)
Sensitivity analysis
Where possible, we will undertake sensitivity analysis to assess the
robustness of results. We will re-analyse data after excluding stud-
ies with high risk of bias and studies that have not performed an
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intention-to-treat analysis. We will conduct sensitivity analysis to
investigate heterogeneous results with the identification and re-
moval of heterogeneous studies. We will conduct sensitivity anal-
ysis to investigate the effect of the choice of model (fixed-effect or
random-effects) on the pooled estimate. For studies at high risk of
attrition bias, we will conduct a best/worse case sensitivity analysis
to assess the impact of missing data on the estimates of effect. If
there are any assumptions for ICC value used in cluster-RCTs we
will perform sensitivity analysis. Other sensitivity analysis may be
undertaken during the review process, that are currently unfore-
seen.
Summary of findings
We will assess the overall quality of evidence of the main review
outcomes using the (GRADE) approach in ’Summary of findings’
table(s) (GRADEWorking Group 2004). The ’Summary of find-
ings’ table(s) will highlight the overall quality of the body of evi-
dence for the main review outcomes, using the GRADE criteria
(study limitations (i.e. risk of bias), consistency of effect, indirect-
ness, imprecision and publication bias). We will use GRADEpro
GDT 2015 software to prepare the ’Summary of findings’ table.
Wehave included a preliminary ’Summary of findings’ table below.
We will also present the results from the pre-specified Sensitivity
analysis and Subgroup analysis and investigation of heterogeneity
when appropriate in ’Summary of findings’ tables.
Exercise or physical activity compared with control in adults with non-advanced colorectal cancer
Population: adults with non-advanced colorectal cancer treated surgically with or without neoadjuvant or adjuvant therapy
Settings: any setting
Intervention: aerobic or resistance training, flexibility or balance training or a combination of these lasting at least 4 weeks
Comparison: control intervention (usual care or no exercise or physical activity intervention)
Outcomes Illustrative compar-
ative risks (95% CI)
*Assumed risk Cor-
responding risk
Control groupExer-
cise group
Relative effect (95%
CI)
No. of participants
(studies)
Quality of the evi-
dence (GRADE)
Comments
Physical function
(measurement tool)
Follow-up: up to 12
weeks
Disease-re-
latedmental health
(measurement tool)
Follow-up: up to 12
weeks
Adverse
events (participants
experiencing at least
one adverse event)
Follow-up: up to 12
weeks
Overall
survival (time inter-
val between enrol-
ment in the study
anddeath of the per-
son from any cause)
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(Continued)
Follow-up: 12
months
Recur-
rence-free survival
(time interval be-
tween date of enrol-
ment in the study
and the date when
colorectal cancer re-
curs or another can-
cer occurs during
the follow-up)
Follow-up: 12
months
Physical fitness
(measurement tool)
Follow-up: up to 12
weeks
Cancer-related fa-
tigue (measurement
tool)
Follow-up: up to 12
weeks
Anthropomet-
ric measurements
(measurement tool)
Follow-up: up to 12
weeks
Health-re-
lated quality of life
(measurement tool)
Follow-up: up to 12
weeks
Levels
of physical activity
(measurement tool)
Follow-up: up to 12
weeks
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The
corresponding risk(and its 95% CI) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
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We will justify and document our judgements about the quality
of the evidence (high, moderate, low or very low) and incorporate
them into the reporting of results for each outcome.
The GRADE system classifies the quality of evidence in one of
four grades:
1. High quality: we are very confident that the true effect lies
close to that of the estimate of the effect;
2. Moderate quality: we are moderately confident in the effect
estimate; the true effect is likely to be close to the estimate of
effect, but there is a possibility that it is substantially different;
3. Low quality: our confidence in the effect estimate is
limited; the true effect may be substantially different from the
estimate of the effect;
4. Very low quality: we have very little confidence in the effect
estimate; the true effect is likely to be substantially different from
the estimate of effect;
The quality of evidence can be downgraded by one (serious con-
cern) or two levels (very serious concern) for the following reasons:
1. Risk of bias;
2. Inconsistency (unexplained heterogeneity, inconsistency of
results);
3. Indirectness (indirect population, intervention, control,
outcomes); and
4. Imprecision (wide confidence intervals, insufficient sample
size or number of events).
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
Cochrane Central Register of Controlled Trials (CENTRAL): year, issue number in the Cochrane Library (searched day, month,
year)
#1 MeSH descriptor: [Colorectal Neoplasms] explode all trees
#2 ((colorect* or colon* or rect* or anal* or anus* or intestin* or bowel*) near/5 (carcinom* or neoplas* or adenocarcinom* or cancer*
or tumor* or tumour* or sarcom* or malignan*)):ti,ab,kw (Word variations have been searched)
#3 #1 or #2
#4 MeSH descriptor: [Exercise] explode all trees
#5 MeSH descriptor: [Exercise Therapy] explode all trees
#6 MeSH descriptor: [Sports] explode all trees
#7 “physical fitness” (Word variations have been searched)
#8 (physical* near/5 (fit* or train* or activ* or endur* or exer*)):ti,ab,kw (Word variations have been searched)
#9 (exercis* near/5 (train* or physical* or activ*)):ti,ab,kw (Word variations have been searched)
#10 sport*:ti,ab,kw (Word variations have been searched)
#11 walk*:ti,ab,kw (Word variations have been searched)
#12 swim*:ti,ab,kw (Word variations have been searched)
#13 pilates*:ti,ab,kw (Word variations have been searched)
#14 tai ji or tai chi or tai-ji or tai-chi:ti,ab,kw (Word variations have been searched)
#15 resistance near/3 train*:ti,ab,kw (Word variations have been searched)
#16 #4 and #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15
#17 #3 and #16
Appendix 2. MEDLINE search strategy
Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid
MEDLINE(R) 1946 to present (day, month, year)
1. exp colorectal neoplasms/
2. ((colorect* or colon* or rect* or anal* or anus* or intestin* or bowel*) adj5 (carcinom* or neoplas* or adenocarcinom* or cancer*
or tumor* or tumour* or sarcom* or malignan*)).mp
3. 1 or 2
4. exp exercise/
5. exp exercise therapy/
6. exp sports/
7. Physical Fitness/
8. (physical* adj5 (fit* or train* or activ* or endur* or exer*)).ti,ab
9. (exercis* adj5 (train* or physical* or activ*)).ti,ab.
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(Continued)
10. sport*.ti,ab.
11. walk*.ti,ab.
12. swim*.ti,ab.
13. pilates.ti,ab.
14. (tai ji or tai chi or tai-ji or tai-chi).ti,ab.
15. (resistance adj3 train*).ti,ab.
16. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
17. 3 and 16
18. randomized controlled trial.pt.
19. controlled clinical trial.pt.
20. randomized.ab.
21. placebo.ab.
22. clinical trials as topic.sh.
23. randomly.ab.
24. trial.ti.
25. 18 or 19 or 20 or 21 or 22 or 23 or 24
26. exp animals/ not humans.sh.
27. 25 not 26
28. 17 and 27
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Appendix 3. Embase search strategy
Ovid Embase: 1974 to year week
1. exp large intestine tumor/
2. ((colorect* or colon* or rect* or anal* or anus* or intestin* or bowel*) adj5 (carcinom* or neoplas* or adenocarcinom* or cancer*
or tumor* or tumour* or sarcom* or malignan*)).mp
3. 1 or 2
4. exp exercise/
5. exp sport/
6. physical fitness/
7. exercise therapy/
8. (physical* adj5 (fit* or train* or activ* or endur* or exer*)).ti,ab
9. (exercis* adj5 (train* or physical* or activ*)).ti,ab.
10. sport*.ti,ab.
11. walk*.ti,ab.
12. swim*.ti,ab.
13. pilates.ti,ab.
14. (tai ji or tai chi or tai-ji or tai-chi).ti,ab.
15. (resistance adj3 train*).ti,ab.
16. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
17. 3 and 16
18. CROSSOVER PROCEDURE.sh.
19. DOUBLE-BLIND PROCEDURE.sh.
20. SINGLE-BLIND PROCEDURE.sh.
21. (crossover* or cross over*).ti,ab.
22. placebo*.ti,ab.
23. (doubl* adj blind*).ti,ab.
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(Continued)
24. allocat*.ti,ab.
25. trial.ti.
26. RANDOMIZED CONTROLLED TRIAL.sh.
27. random*.ti,ab.
28. 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27
29. (exp animal/ or exp invertebrate/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans or man
or men or wom?n).ti.)
30. 28 not 29
31. 17 and 30
Appendix 4. Criteria for judging risk of bias in the ’Risk of bias’ assessment tool
Random sequence generation
Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence
Criteria for a judgement of ‘low risk’ of bias The investigators describe a random component in the sequence
generation process such as:
• referring to a random number table;
• using a computer random number generator;
• ·coin tossing;
• ·shuffling cards or envelopes;
• throwing dice;
• drawing of lots;
• minimisation*.
*Minimisation may be implemented without a random element,
and this is considered to be equivalent to being random
Criteria for the judgement of ‘high risk’ of bias The investigators describe a non-random component in the se-
quence generation process. Usually, the description would involve
some systematic, non-random approach, for example:
• sequence generated by odd or even date of birth;
• sequence generated by some rule based on date (or day) of
admission;
• sequence generated by some rule based on hospital or clinic
record number.
Other non-random approaches happen much less frequently than
the systematic approaches mentioned above and tend to be ob-
vious. They usually involve judgement or some method of non-
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(Continued)
random categorisation of participants, for example:
• allocation by judgement of the clinician;
• allocation by preference of the participant;
• allocation based on the results of a laboratory test or a series
of tests;
• allocation by availability of the intervention
Criteria for the judgement of ‘unclear risk’ of bias. Insufficient information about the sequence generation process to
permit judgement of ‘low risk’ or ‘high risk’
Allocation concealment
Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment
Criteria for a judgement of ‘low risk’ of bias Participants and investigators enrolling participants could not
foresee assignment because one of the following, or an equivalent
method, was used to conceal allocation:
• central allocation (including telephone, web-based and
pharmacy-controlled randomisation);
• sequentially numbered drug containers of identical
appearance;
• sequentially numbered, opaque, sealed envelopes.
Criteria for the judgement of ‘high risk’ of bias Participants or investigators enrolling participants could possibly
foresee assignments and thus introduce selection bias, such as al-
location based on:
• using an open random allocation schedule (e.g. a list of
random numbers);
• assignment envelopes were used without appropriate
safeguards (e.g. if envelopes were unsealed or nonopaque or not
sequentially numbered);
• alternation or rotation;
• date of birth;
• case record number;
• any other explicitly unconcealed procedure.
Criteria for the judgement of ‘unclear risk’ of bias Insufficient information to permit judgement of ‘low risk’ or ‘high
risk’. This is usually the case if the method of concealment is not
described or not described in sufficient detail to allow a definite
judgement - for example if the use of assignment envelopes is de-
scribed, but it remains unclear whether envelopes were sequen-
tially numbered, opaque and sealed
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions by participants and personnel during the study
Criteria for a judgement of ‘low risk’ of bias Any one of the following:
• no blinding or incomplete blinding, but the review authors
judge that the outcome is not likely to be influenced by lack of
blinding;
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(Continued)
• blinding of participants and key study personnel ensured,
and unlikely that the blinding could have been broken.
Criteria for the judgement of ‘high risk’ of bias Any one of the following:
• no blinding or incomplete blinding, and the outcome is
likely to be influenced by lack of blinding;
• blinding of key study participants and personnel
attempted, but likely that the blinding could have been broken,
and the outcome is likely to be influenced by lack of blinding.
Criteria for the judgement of ‘unclear risk’ of bias Any one of the following:
• insufficient information to permit judgement of ‘low risk’
or ‘high risk’;
• the study did not address this outcome.
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by outcome assessors
Criteria for a judgement of ‘low risk’ of bias Any one of the following:
• no blinding of outcome assessment, but the review authors
judge that the outcome measurement is not likely to be
influenced by lack of blinding;
• blinding of outcome assessment ensured, and unlikely that
the blinding could have been broken.
Criteria for the judgement of ‘high risk’ of bias Any one of the following:
• no blinding of outcome assessment, and the outcome
measurement is likely to be influenced by lack of blinding;
• blinding of outcome assessment, but likely that the
blinding could have been broken, and the outcome
measurement is likely to be influenced by lack of blinding.
Criteria for the judgement of ‘unclear risk’ of bias Any one of the following:
• insufficient information to permit judgement of ‘low risk’
or ‘high risk’;
• the study did not address this outcome.
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete outcome data
Criteria for a judgement of ‘low risk’ of bias Any one of the following:
• no missing outcome data;
• reasons for missing outcome data unlikely to be related to
true outcome (for survival data, censoring unlikely to be
introducing bias);
• missing outcome data balanced in numbers across
intervention groups, with similar reasons for missing data across
groups;
• for dichotomous outcome data, the proportion of missing
20Physical activity and exercise interventions for disease-related physical and mental health during and following treatment in people with
non-advanced colorectal cancer (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
outcomes compared with observed event risk not enough to have
a clinically relevant impact on the intervention effect estimate;
• for continuous outcome data, plausible effect size
(difference in means or standardised difference in means) among
missing outcomes not enough to have a clinically relevant
impact on observed effect size;
• missing data have been imputed using appropriate
methods.
Criteria for the judgement of ‘high risk’ of bias Any one of the following:
• reason for missing outcome data likely to be related to true
outcome, with either imbalance in numbers or reasons for
missing data across intervention groups;
• for dichotomous outcome data, the proportion of missing
outcomes compared with observed event risk enough to induce
clinically relevant bias in intervention effect estimate;
• for continuous outcome data, plausible effect size
(difference in means or standardised difference in means) among
missing outcomes enough to induce clinically relevant bias in
observed effect size;
• ‘as-treated’ analysis done with substantial departure of the
intervention received from that assigned at randomisation;
• potentially inappropriate application of simple imputation.
Criteria for the judgement of ‘unclear risk’ of bias Any one of the following:
• insufficient reporting of attrition/exclusions to permit
judgement of ‘low risk’ or ‘high risk’ (e.g. number randomised
not stated, no reasons for missing data provided);
• the study did not address this outcome.
Selective reporting
Reporting bias due to selective outcome reporting
Criteria for a judgement of ‘low risk’ of bias Any of the following:
• the study protocol is available and all of the study’s pre-
specified (primary and secondary) outcomes that are of interest
in the review have been reported in the pre-specified way;
• the study protocol is not available but it is clear that the
published reports include all expected outcomes, including those
that were pre-specified (convincing text of this nature may be
uncommon).
Criteria for the judgement of ‘high risk’ of bias Any one of the following:
• not all of the study’s pre-specified primary outcomes have
been reported;
• one or more primary outcomes is reported using
measurements, analysis methods or subsets of the data (e.g.
subscales) that were not pre-specified;
• one or more reported primary outcomes were not pre-
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specified (unless clear justification for their reporting is provided,
such as an unexpected adverse effect);
• one or more outcomes of interest in the review are reported
incompletely so that they cannot be entered in a meta-analysis;
• the study report fails to include results for a key outcome
that would be expected to have been reported for such a study.
Criteria for the judgement of ‘unclear risk’ of bias Insufficient information to permit judgement of ‘low risk’ or ‘high
risk’. It is likely that the majority of studies will fall into this
category
Other bias
Bias due to problems not covered elsewhere in the table
Criteria for a judgement of ‘low risk’ of bias The study appears to be free of other sources of bias.
Criteria for the judgement of ‘high risk’ of bias There is at least one important risk of bias. For example, the study:
• had a potential source of bias related to the specific study
design used; or
• has been claimed to have been fraudulent; or
• had some other problem.
Criteria for the judgement of ‘unclear risk’ of bias There may be a risk of bias, but there is either:
• insufficient information to assess whether an important risk
of bias exists; or
• insufficient rationale or evidence that an identified problem
will introduce bias.
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